针对肝细胞癌的定制质子束疗法:通过多学科方法解决未满足的需求
Jeong Ha Lee1, Nalee Kim1, Jeong Il Yu1
1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
概括
质子束疗法 (PBT) 为无法接受标准治疗的肝细胞癌 (HCC) 患者提供有利的局部控制和生存结果. 这项研究支持PBT作为一个有前途的替代本地废除HCC的方法.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
背景情况:
- 自2015年以来,三星医疗中心已经治疗了2000例肝细胞癌 (HCC) 病例.
- 接受治疗的患者无法接受巴塞罗那诊所肝癌 (BCLC) 标准指南治疗.
- 质子束疗法 (PBT) 被评价为一种替代的局部治疗方式.
研究的目的:
- 评估PBT在HCC患者中的临床结果.
- 探索PBT作为替代本地废除方式的潜在作用.
- 评估局部进展,整体存活率和毒性.
主要方法:
- 对接受PBT治疗的HCC患者的回顾性审查.
- 主要终点:没有局部进展 (FFLP).
- 二级终点:整体存活率 (OS) 和毒性.
主要成果:
- 在治疗期间,两年的FFLP超过了90%.
- 两年FFLP的发病率因BCLC的阶段而异,从87.6% (C阶段) 到98.5% (B阶段).
- 三年后的OS率在37.2% (C阶段) 到81.1% (0阶段) 之间.
结论:
- 在HCC患者中,PBT表现出有利的局部控制和生存结果.
- PBT 作为 HCC 的一个有前途的局部消毒疗法.
- PBT解决了HCC患者无法接受标准治疗的未满足的治疗需求.
更多相关视频
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.8K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.3K
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
